CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law about the $45 Merger Offer from AbbVie

Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately$8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichm ...